A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women

NCT01250145 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

251

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis, Postmenopausal

Interventions

DRUG: LY333334
DRUG: Placebo

Sponsor

Eli Lilly and Company